Exact Mass: 293.1124
Exact Mass Matches: 293.1124
Found 186 metabolites which its exact mass value is equals to given mass value 293.1124,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Oxaprozin
Oxaprozin is only found in individuals that have used or taken this drug. It is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.Anti-inflammatory effects of Oxaprozin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Oxaprozin is a non-selective NSAID, with a cell assay system showing lower COX-2 selectivity implying higher COX-1 selectivity. M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AE - Propionic acid derivatives D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties[1][2].
N-Acetylmuramate
This compound belongs to the family of N-acyl-alpha-hexosamines. These are carbohydrate derivatives containing a hexose moeity in which the oxygen atom is replaced by an n-acyl group. KEIO_ID A191
4-(8-Methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)benzenamine
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D020011 - Protective Agents
(3R)-3,4-Dihydroxy-3-(hydroxymethyl)butanenitrile 4-glucoside
(3R)-3,4-Dihydroxy-3-(hydroxymethyl)butanenitrile 4-glucoside is found in cereals and cereal products. (3R)-3,4-Dihydroxy-3-(hydroxymethyl)butanenitrile 4-glucoside is a constituent of barley (Hordeum vulgare). Constituent of barley (Hordeum vulgare). (3R)-3,4-Dihydroxy-3-(hydroxymethyl)butanenitrile 4-glucoside is found in barley and cereals and cereal products.
Galactosyl 4-hydroxyproline
Galactosyl 4-hydroxyproline is found in cereals and cereal products. Galactosyl 4-hydroxyproline is isolated from hydrolyzed wheat endosperm. Isolated from hydrolysed wheat endosperm. Galactosyl 4-hydroxyproline is found in cereals and cereal products.
4-Hydroxyproline galactoside
4-Hydroxyproline galactoside is found in cereals and cereal products. 4-Hydroxyproline galactoside is isolated from hydrolyzed wheat endosperm. Isolated from hydrolysed wheat endosperm. 4-Hydroxyproline galactoside is found in cereals and cereal products.
1-(4-Methoxybenzyl)-6,7-methylenedioxyisoquinoline
6-hydroxy-3,3-dimethyl-12H-pyrano[2,3-c]acridin-7-one
2-acetamido-4-O-((S)-1-carboxyethyl)-2-deoxy-D-glucopyranose|2-acetamido-4-O-<(S)-1-carboxyethyl>-2-deoxy-D-glucopyranose
5-acetyl-3-deoxyadenosine|5-O-acetyl-3-deoxyadenosine|9-(5-O-acetyl-3-deoxy-beta-D-erythro-pentofuranosyl)adenine
(8aR,9R,11R,12aR)-3-chloro-6,7,8,8a,9,10,11,12-octahydro-14-hydroxy-11-methyl-4H-9,1-ethanylylidenebenzo[i]quinolizin-13-one|2-chlorohuperzine E
oxaprozin
M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AE - Propionic acid derivatives D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties[1][2].
Naphthol AS-OL
CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5054; ORIGINAL_PRECURSOR_SCAN_NO 5049 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5079; ORIGINAL_PRECURSOR_SCAN_NO 5074 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5032; ORIGINAL_PRECURSOR_SCAN_NO 5030 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5075; ORIGINAL_PRECURSOR_SCAN_NO 5073 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5061; ORIGINAL_PRECURSOR_SCAN_NO 5057 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5055; ORIGINAL_PRECURSOR_SCAN_NO 5054 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9521; ORIGINAL_PRECURSOR_SCAN_NO 9519 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9583; ORIGINAL_PRECURSOR_SCAN_NO 9581 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9626; ORIGINAL_PRECURSOR_SCAN_NO 9624 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9630; ORIGINAL_PRECURSOR_SCAN_NO 9625 CONFIDENCE standard compound; INTERNAL_ID 649; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9646; ORIGINAL_PRECURSOR_SCAN_NO 9645
Galactosyl 4-hydroxyproline
4-Hydroxyproline galactoside
(3R)-3,4-Dihydroxy-3-(hydroxymethyl)butanenitrile 4-glucoside
N-Benzyl-1-(2,4-dimethoxyphenyl)methanamine hydrochloride
Benzoic acid, 4-[(3-formyl-1H-indol-1-yl)methyl]-, methyl ester (9CI)
Benzoic acid, 4-[(3-formyl-2-methyl-1H-indol-1-yl)methyl]- (9CI)
2-(3-Methoxyphenyl)-6-methylquinoline-4-carboxylic acid
2-(2-Methoxyphenyl)-8-methylquinoline-4-carboxylic acid
2-(3-Methoxyphenyl)-8-methylquinoline-4-carboxylic acid
2-(4-Methoxyphenyl)-8-methylquinoline-4-carboxylic acid
1-(4-nitrophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)ANILINE DIHYDROCHLORIDE
ethyl 4-(4-fluorophenyl)-1-methyl-2,6-dioxopiperidine-3-carboxylate
N-(2-OXO-5-PHENYL-2,3-DIHYDRO-1H-BENZO[E][1,4]DIAZEPIN-3-YL)-ACETAMIDE
3-Carboxy-5-nitrobenzeneboronic acid pinacol ester
2-amino-6-(4-phenylmethoxyphenyl)-1H-pyrimidin-4-one
N-(3-oxo-1-phenyl-2H-pyrazol-4-yl)-2-phenyl-acetamide
N-(2-(2-Methoxyphenoxy)ethyl)benzylamine hydrochloride
1-(BETA-D-2-DEOXYRIBOFURANOSYL)-4-(1,2,4-TRIAZOL-1-YL)-5-METHYLPYRIMIDIN-2-ONE
Methoxypolyethylene glycol 5,000 acetic acid N-succinimidyl ester
4-Quinolinecarboxylic acid, 2-(4-Methoxyphenyl)-, Methyl ester
1H-Indole-1-acetamide,3-formyl-2-methyl-N-2-pyridinyl-(9CI)
1H-INDOL-3-YL[3-(4-METHOXYPHENYL)OXIRAN-2-YL]METHANONE
2-Cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-methanol
trans-3-Ethoxycarbonyl-4-(4-flurophenyl)-N-methyl piperdine-2,6-dione
2-amino-3-nitro-4-phenyl-5,6,7,8-tetrahydronaphthalene-1-carbonitrile
2-amino-9-((3aS,4S,6S,6aR)-3a,6-dihydroxyhexahydro-1H-cyclopenta[c]furan-4-yl)-1,9-dihydro-6H-purin-6-one
Benzeneethanamine,3-methoxy-4-(phenylmethoxy)-, hydrochloride (1:1)
3-NITRO-4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZOIC ACID
N-(4-ethylphenyl)-4-oxo-3H-phthalazine-1-carboxamide
7-Methyl-4-oxo-2-[(phenylmethyl)amino]-3-pyrido[1,2-a]pyrimidinecarboxaldehyde
9-Amino-5-(2-aminopyrimidin-4-yl)pyrido[3,2:4,5]pyrrolo[1,2-c]pyrimidin-4-ol
3-{[(1R)-1-phenylethyl]amino}-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione
N,N-Dimethyl-N-(acetyl)-N-(7-nitrobenz-2-oxa-1,3-diazol-4-YL)ethylenediamine
4-(2-Furanyl)-3-methyl-5-(4-methylphenyl)-2,4-dihydropyrrolo[3,4-c]pyrazol-6-one
N-(4-hydroxyphenyl)-3-methoxy-2-naphthalenecarboxamide
3-[(2-Hydroxyphenyl)hydrazinylidene]-1-prop-2-enyl-2-indolone
4-methyl-N-[(1-oxopentylhydrazo)-sulfanylidenemethyl]benzamide
5-(4-methylphenyl)-N-(3-pyridinylmethyl)-3-isoxazolecarboxamide
4-methylbenzoic acid [2-(1H-indol-3-yl)-2-oxoethyl] ester
3-[1-(3-Methoxypropyl)-5-thiophen-2-yl-2-pyrrolyl]propanoic acid
4-(6-Quinolinyl)-1,3,4,6,7,8-hexahydroquinazoline-2,5-dione
2-[[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)-4-oxanyl]oxy]propanoic acid
4-[3,4,5-Trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypyrrolidine-2-carboxylic acid
(2S)-2-azaniumyl-5-{[(1S)-1-carboxylato-2-phenylethyl]amino}-5-oxopentanoate
6-Methyl-3-[2-(4-methylphenyl)-2-oxoethyl]-1,4-benzoxazin-2-one
4-Acetyl-5-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidine-2,3-dione
2-amino-5-(aminomethyl)-7-[4-hydroxy-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-3H-pyrrolo[2,3-d]pyrimidin-4-one
GYKI 52466
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D020011 - Protective Agents
2-[3-Acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoic acid
gamma-Glu-Phe(1-)
A peptide anion obtained by deprotonation of both carboxy groups and protonation of the glutamyl amino group of gamma-Glu-Phe. Major species at pH 7.3.
